Duska Separovic1,2, Anthony F Shields2,3, Philip A Philip2,3, Jacek Bielawski4, Alicja Bielawska4, Jason S Pierce4, Adi L Tarca5,6. 1. Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, U.S.A. jmjilyss999@gmail.com. 2. Karmanos Cancer Institute, Wayne State University, Detroit, MI, U.S.A. 3. Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, U.S.A. 4. Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, U.S.A. 5. Department of Obstetrics and Gynecology, School of Medicine, Wayne State University, Detroit, MI, U.S.A. 6. Department of Computer Science, College of Engineering, Wayne State University, Detroit, MI, U.S.A.
Abstract
BACKGROUND/AIM: Because patients with cancer of apparently equivalent stage often have different outcomes, it is necessary to gather additional information to complement cancer staging. Dysregulated sphingolipid metabolism contributes to carcinogenesis. In this retrospective pilot study, we tested the hypothesis that changes in serum levels of sphingolipids are associated with stage IV colorectal cancer (CRC). PATIENTS AND METHODS: We used commercially available serum samples from healthy males and patients with CRC (adenocarcinoma of the large intestine, stage IV with metastases). Blood samples were obtained immediately prior to anesthesia/surgery. We measured sphingolipid levels in sera using mass spectrometry. RESULTS: In serum of patients with CRC, the levels of C16-, C18-, C18:1-, and C24:1-ceramide, as well as those of sphingosine, were significantly higher than those of controls. In contrast, the levels of C24-sphingomyelin were significantly lower than those of controls. A global test of association showed that ceramides and sphingomyelins but not hexosylceramides were significantly associated with stage IV CRC. CONCLUSION: Sphingolipids have a potential of serving as novel, non-invasive, inexpensive, and effective blood-based biomarkers to complement CRC staging for better prognosis and more personalized medicine. Copyright
BACKGROUND/AIM: Because patients with cancer of apparently equivalent stage often have different outcomes, it is necessary to gather additional information to complement cancer staging. Dysregulated sphingolipid metabolism contributes to carcinogenesis. In this retrospective pilot study, we tested the hypothesis that changes in serum levels of sphingolipids are associated with stage IV colorectal cancer (CRC). PATIENTS AND METHODS: We used commercially available serum samples from healthy males and patients with CRC (adenocarcinoma of the large intestine, stage IV with metastases). Blood samples were obtained immediately prior to anesthesia/surgery. We measured sphingolipid levels in sera using mass spectrometry. RESULTS: In serum of patients with CRC, the levels of C16-, C18-, C18:1-, and C24:1-ceramide, as well as those of sphingosine, were significantly higher than those of controls. In contrast, the levels of C24-sphingomyelin were significantly lower than those of controls. A global test of association showed that ceramides and sphingomyelins but not hexosylceramides were significantly associated with stage IV CRC. CONCLUSION:Sphingolipids have a potential of serving as novel, non-invasive, inexpensive, and effective blood-based biomarkers to complement CRC staging for better prognosis and more personalized medicine. Copyright
Authors: Samar M Hammad; Jason S Pierce; Farzan Soodavar; Kent J Smith; Mohammed M Al Gadban; Barbara Rembiesa; Richard L Klein; Yusuf A Hannun; Jacek Bielawski; Alicja Bielawska Journal: J Lipid Res Date: 2010-07-21 Impact factor: 5.922
Authors: Krzysztof Kurek; Bartłomiej Łukaszuk; Dominika M Piotrowska; Patrycja Wiesiołek; Anna Małgorzata Chabowska; Małgorzata Zendzian-Piotrowska Journal: Biomed Res Int Date: 2013-09-05 Impact factor: 3.411
Authors: Rebekah J Nicholson; Marie K Norris; Annelise M Poss; William L Holland; Scott A Summers Journal: Annu Rev Nutr Date: 2022-05-18 Impact factor: 9.323
Authors: Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández Journal: Cancers (Basel) Date: 2022-04-19 Impact factor: 6.575
Authors: Adam R Markowski; Agnieszka U Błachnio-Zabielska; Katarzyna Guzińska-Ustymowicz; Agnieszka Markowska; Karolina Pogodzińska; Kamila Roszczyc; Justyna Zińczuk; Piotr Zabielski Journal: Biomolecules Date: 2020-04-19
Authors: Kamilah Castro; Achilles Ntranos; Mario Amatruda; Maria Petracca; Peter Kosa; Emily Y Chen; Johannes Morstein; Dirk Trauner; Corey T Watson; Michael A Kiebish; Bibiana Bielekova; Matilde Inglese; Ilana Katz Sand; Patrizia Casaccia Journal: EBioMedicine Date: 2019-04-10 Impact factor: 8.143
Authors: Kristine C Olson; Katharine B Moosic; Marieke K Jones; Paige M K Larkin; Thomas L Olson; Mariella F Toro; Todd E Fox; David J Feith; Thomas P Loughran Journal: Cancer Med Date: 2020-07-25 Impact factor: 4.452
Authors: Zoë Jukes; Anne Freier; Panagiotis A Vorkas; Jia V Li; Maria Glymenaki; Richard Brown; Lee Parry; Elizabeth Want Journal: Biosci Rep Date: 2021-03-26 Impact factor: 3.840
Authors: Yahui Zhu; Li Gu; Xi Lin; Jinmiao Zhang; Yi Tang; Xinyi Zhou; Bingjun Lu; Xingrong Lin; Cheng Liu; Edward V Prochownik; Youjun Li Journal: JCI Insight Date: 2022-02-08
Authors: Maura E Walker; Vanessa Xanthakis; Linda R Peterson; Meredith S Duncan; Joowon Lee; Jiantao Ma; Sherman Bigornia; Lynn L Moore; Paula A Quatromoni; Ramachandran S Vasan; Paul F Jacques Journal: J Nutr Date: 2020-11-19 Impact factor: 4.798